Baseline patient characteristics of cohort
| Parameter . | n (%) Total cohort = 11 . |
|---|---|
| Age at initial diagnosis, y | |
| <1 | 3 (27) |
| 1-9.9 | 7 (64) |
| ≥10 | 1 (9) |
| Sex | |
| Female | 4 (36) |
| Male | 7 (64) |
| Ethnicity | |
| Not Hispanic or Latino | 5 (45) |
| Hispanic or Latino | 6 (55) |
| Initial diagnosis | |
| Standard-risk ALL | 5 (45) |
| High-risk ALL | 5 (45) |
| CD19+ MPAL | 1 (9) |
| Cytogenetics | |
| KMT2A rearranged∗ | 3 (27) |
| Philadelphia-chromosome positive | 2 (18) |
| Philadelphia-like (CRLF2 fusion) | 2 (18) |
| Hyperdiploidy | 2 (18) |
| Hypodiploidy | 1 (9) |
| iAMP21 | 1 (9) |
| Remission status | |
| CR1 | 9 (82) |
| CR2 | 2 (18) |
| MRD status before blinatumomab† | |
| Negative | 10 (91) |
| Positive | 1 (9) |
| Reason for blinatumomab | |
| Toxicity precluding chemotherapy | 4 (36) |
| Other | 7 (64) |
| Therapy before blinatumomab | |
| Induction | 6 (55) |
| Additional therapy | 5 (45) |
| Parameter . | n (%) Total cohort = 11 . |
|---|---|
| Age at initial diagnosis, y | |
| <1 | 3 (27) |
| 1-9.9 | 7 (64) |
| ≥10 | 1 (9) |
| Sex | |
| Female | 4 (36) |
| Male | 7 (64) |
| Ethnicity | |
| Not Hispanic or Latino | 5 (45) |
| Hispanic or Latino | 6 (55) |
| Initial diagnosis | |
| Standard-risk ALL | 5 (45) |
| High-risk ALL | 5 (45) |
| CD19+ MPAL | 1 (9) |
| Cytogenetics | |
| KMT2A rearranged∗ | 3 (27) |
| Philadelphia-chromosome positive | 2 (18) |
| Philadelphia-like (CRLF2 fusion) | 2 (18) |
| Hyperdiploidy | 2 (18) |
| Hypodiploidy | 1 (9) |
| iAMP21 | 1 (9) |
| Remission status | |
| CR1 | 9 (82) |
| CR2 | 2 (18) |
| MRD status before blinatumomab† | |
| Negative | 10 (91) |
| Positive | 1 (9) |
| Reason for blinatumomab | |
| Toxicity precluding chemotherapy | 4 (36) |
| Other | 7 (64) |
| Therapy before blinatumomab | |
| Induction | 6 (55) |
| Additional therapy | 5 (45) |
CR1, first complete remission; CR2, second complete remission; iAMP21, intrachromosomal amplification of chromosome 21; MPAL, mixed phenotypic acute leukemia.
All 3 patients with KMT2A-rearranged disease had infant leukemia; one of these 3 patients had CD19+ MPAL. Among the remaining 8 patients, 3 had National Cancer Institute high-risk B-ALL.
MRD negativity was defined as <0.01% disease by flow cytometry. The patient who was MRD positive (1.1%) achieved MRD negativity after blinatumomab.